The U.S. Food and Drug Administration gave the green light on Thursday to Gilead Sciences Inc.'s (NASDAQ: GILD) Bixlenvo, a new treatment for adults with HIV who are already virologically suppressed. That's a fancy way of saying the virus is undetectable in their blood, thanks to their current meds.
Bixlenvo packs 75 mg of bictegravir and 50 mg of lenacapavir into a single pill. It's the smallest once-daily single-tablet regimen available today, which is a big deal for patients juggling complex drug cocktails.
This is also the first and only single-tablet option for people who can't use other single-tablet therapies because their regimens are too complicated. For those patients, Bixlenvo simplifies things considerably. Before starting, patients take a two-day initiation dose of Sunlenca, then switch to the once-daily Bixlenvo pill.
What the Clinical Trials Showed
The FDA based its decision on data from the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials. These studies looked at virologically suppressed adults who switched from complex multi-tablet regimens or from Biktarvy, another Gilead HIV drug.
The results were encouraging: patients maintained virologic suppression at the 48-week mark. The drug was generally well-tolerated, with no new safety concerns popping up. The most common side effects, affecting at least 2% of participants, were headache, nausea, and diarrhea.
Who Was in the Studies?
The ARTISTRY-1 trial enrolled a notably older group of patients, with a median age of 60 years. That's the oldest population ever in a Phase 3 HIV-1 registrational trial. These weren't newbies to HIV treatment either. On average, participants had been on therapy for 28 years.
At the start of the trial, these patients were taking anywhere from two to 11 pills a day, often with multiple doses throughout the day, because they had high levels of antiretroviral resistance. Switching to Bixlenvo not only cut down the pill burden but also improved patient-reported treatment satisfaction and certain fasting lipid parameters. The ARTISTRY-2 trial showed that the switch didn't significantly affect overall weight, which is a plus since weight gain can be a concern with some HIV meds.
As for the stock, Gilead shares were up 0.49% at $146.40 at the time of publication on Monday, according to market data.
